Tweet CAMBRIDGE, MA, Immuneering today announced an additional $3 million in funding.

This new total reflects additional funds raised after the company's previously disclosed completion of $17 million.

About Immuneering CorporationImmuneering leverages more than a decade of leadership in bioinformatics to develop new medicines unlikely to be found by traditional drug discovery methods.

Its current pipeline of drug candidates is focused on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis.

Utilizing its proprietary Disease Cancelling Technology, the company engineers medicines that reverse a disease signal across many relevant genes. | To read full story, visit https://startuparound.com/read/1579829407.2981713/Immuneering-Lands-Additional-$3M?ref=audio_experience